IRMD vs PRCT vs ISRG vs NVCR

For growth investors, PROCEPT BioRobotics Corporation (PRCT) is the stronger pick with 37.

2% revenue growth year-over-year, versus 8. 3% for NovoCure Limited (NVCR). IRadimed Corporation (IRMD) offers the better valuation at 49. 6x trailing P/E (42. 9x forward), making it the more compelling value choice. Analysts rate IRadimed Corporation (IRMD) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, IRadimed Corporation (IRMD) is the cheapest at 49.

6x versus Intuitive Surgical, Inc. at 57. 6x. On forward P/E, IRadimed Corporation is actually cheaper at 42. 9x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: IRadimed Corporation wins at 0. 58x versus Intuitive Surgical, Inc. 's 2. 01x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, IRadimed Corporation (IRMD) delivered a total return of +214.

1%, compared to -91. 3% for NovoCure Limited (NVCR). Over 10 years, the gap is even starker: ISRG returned +554. 2% versus PRCT's -39. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), IRadimed Corporation (IRMD) is the lower-risk stock at 0.

85β versus NovoCure Limited's 2. 20β — meaning NVCR is approximately 159% more volatile than IRMD relative to the S&P 500. On balance sheet safety, Intuitive Surgical, Inc. (ISRG) carries a lower debt/equity ratio of 2% versus 85% for NovoCure Limited — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), PROCEPT BioRobotics Corporation (PRCT) is pulling ahead at 37.

2% versus 8. 3% for NovoCure Limited (NVCR). On earnings-per-share growth, the picture is similar: Intuitive Surgical, Inc. grew EPS 22. 6% year-over-year, compared to 1. 7% for PROCEPT BioRobotics Corporation. Over a 3-year CAGR, PRCT leads at 60. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Intuitive Surgical, Inc.

(ISRG) is the more profitable company, earning 28. 4% net margin versus -31. 0% for PROCEPT BioRobotics Corporation — meaning it keeps 28. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IRMD leads at 31. 2% versus -33. 7% for PRCT. At the gross margin level — before operating expenses — IRMD leads at 76. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, IRadimed Corporation (IRMD) is the more undervalued stock at a PEG of 0. 58x versus Intuitive Surgical, Inc. 's 2. 01x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, IRadimed Corporation (IRMD) trades at 42. 9x forward P/E versus 43. 8x for Intuitive Surgical, Inc. — 0. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NVCR: 99. 0% to $33. 50.

In this comparison, IRMD (1.

3% yield) pays a dividend. PRCT, ISRG, NVCR do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, IRadimed Corporation (IRMD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

85), 1. 3% yield, +433. 9% 10Y return). NovoCure Limited (NVCR) carries a higher beta of 2. 20 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (IRMD: +433. 9%, NVCR: +30. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: IRMD is a small-cap quality compounder stock; PRCT is a small-cap high-growth stock; ISRG is a mid-cap high-growth stock; NVCR is a small-cap quality compounder stock. IRMD pays a dividend while PRCT, ISRG, NVCR do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.